
Novo Nordisk on Friday presented the full results of the initial test phases of the weight loss drug amycretin. (Archive photo). Photo: Tom Little/Reuters
New unveils US weight loss drug test results
Novo Nordisk presented full results from initial test phases of amycretin at a diabetes conference in Chicago. Amycretin aided weight loss of over 24%. Tests showed that overweight patients lost 22% after 36 weeks with a 20 mg dose, and 24.3% with a 60 mg dose. In pill form, a 12-week regime...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?